Recommendations of the informal consultation on issues for clinical product development for human african trypanosomiasis : Geneva, Switzerland, 9-10 September 2004
Other TitlesRecommandations de la consultation informelle sur les questions relatives au développement de produits cliniques pour la trypanosomiase humaine africaine, Genève, Suisse, 9-10 Septembre 2004
World Health Organization. (2007). Recommendations of the informal consultation on issues for clinical product development for human african trypanosomiasis : Geneva, Switzerland, 9-10 September 2004. Geneva : World Health Organization. http://www.who.int/iris/handle/10665/69727
Gov't Doc #WHO/CDS/NTD/IDM/2007.1
Other Language Versionsfrançais
MetadataShow full item record
Showing items related by title and MeSH subject.
Human African trypanosomiasis: update of the methodological framework for clinical trials: report of the first meeting of the Development of New Tools subgroup, Geneva, 24 September 2014 World Health Organization (WHO/HTM/NTD/IDM/2015.5, 2015)
Report on a meeting of the Product Development Team for African Trypanosomiasis Chemotherapy to review the comparative study of the 14-day versus the 7-day treatment of late stage t.b. gamiense African trypanosomiasis with eflornithine : WHO, Geneva, 14 July 1998 UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Product Development Team for African Trypanosomiasis Chemotherapy (TDR/DDR/98.1, 1998)
Control of human african trypanosomiasis: a strategy for the African Region: report of the Regional Director Regional Committee for Africa, 55 (AFR/RC55/11, 2011-06-23)1. Human African trypanosomiasis (HAT) is caused by trypanosomes that are transmitted by the tsetse fly. HAT is the only vector-borne parasitic disease with a geographical distribution limited to the African continent. Populations in the age group 15-45 years living in remote rural areas are the most affected, leading to economic loss and social misery. 2. In the early 1960s, the prevalence of HAT had been reduced to very low levels (prevalence rate less than one case per 10 000 inhabitants). Unfortunately, due to lack of regular surveillance ...